Evidence map›Paper›PMID 37727809›Full record

ArticleFrontiers in cellular and infection microbiology2023

Interspecies comparison of the early transcriptomic changes associated with hepatitis B virus exposure in human and macaque immune cell populations.

Armando Andres Roca Suarez, Séverine Planel, Xavier Grand, Céline Couturier, Trang Tran, Fabrice Porcheray, Jérémie Becker, Frédéric Reynier, Ana Delgado, Elodie Cascales and 11 more

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Armando Andres Roca SuarezINSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, France.
Séverine PlanelBIOASTER, Institut de Recherche Technologique, Lyon, France.
Xavier GrandINSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, France.
Céline CouturierBIOASTER, Institut de Recherche Technologique, Lyon, France.
Trang TranBIOASTER, Institut de Recherche Technologique, Lyon, France.
Fabrice PorcherayBIOASTER, Institut de Recherche Technologique, Lyon, France.
Jérémie BeckerBIOASTER, Institut de Recherche Technologique, Lyon, France.
Frédéric ReynierBIOASTER, Institut de Recherche Technologique, Lyon, France.
Ana DelgadoBIOASTER, Institut de Recherche Technologique, Lyon, France.
Elodie CascalesBIOASTER, Institut de Recherche Technologique, Lyon, France.
Loïc PeyrotBIOASTER, Institut de Recherche Technologique, Lyon, France.
Andrea TamelliniBIOASTER, Institut de Recherche Technologique, Lyon, France.
Adrien SaliouBIOASTER, Institut de Recherche Technologique, Lyon, France.
Céline ElieBIOASTER, Institut de Recherche Technologique, Lyon, France.
Chloé BaumBIOASTER, Institut de Recherche Technologique, Lyon, France.
Bao Quoc VuongDepartment of Biology, The City College of New York, New York, NY, United States.
Barbara TestoniINSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, France.
Pierre RoquesCEA, Institut François Jacob, Fontenay-aux-Roses, France.
Fabien ZoulimINSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, France.
Uzma HasanINSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, France.
Isabelle CheminINSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Hepatitis B virus (HBV) infection affects 300 million individuals worldwide, representing a major factor for the development of hepatic complications. Although existing antivirals are effective in suppressing replication, eradication of HBV is not achieved. Therefore, a multi-faceted approach involving antivirals and immunomodulatory agents is required. Non-human primates are widely used in pre-clinical studies due to their close evolutionary relationship to humans. Nonetheless, it is fundamental to identify the differences in immune response between humans and these models. Thus, we performed a transcriptomic characterization and interspecies comparison of the early immune responses to HBV in human and cynomolgus macaques. Methods: We characterized early transcriptomic changes in human and cynomolgus B cells, T cells, myeloid and plasmacytoid dendritic cells (pDC) exposed to HBV Results: HBV induced a wide variety of transcriptional changes in all cell types, with common genes between species representing only a small proportion. In particular, interferon gamma signaling was repressed in human pDCs. At the gene level, interferon gamma inducible protein 16 ( Conclusion: Our characterization of early transcriptomic changes induced by HBV in humans and cynomolgus macaques represents a useful resource for the identification of shared and divergent host responses, as well as potential immune targets against HBV.

Indexed as

Hepatitis BTranscriptomeAnimalsAntiviral AgentsChoreaHepatitis B virusHumansInterferon-gammaMacaca fascicularisAntiviral AgentsInterferon-gammaHBVimmune responsemacaquePBMCtranscriptomics

Identifiers

PMID37727809
PMCPMC10505653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.